NCT02442206View on ClinicalTrials.gov

Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 18, 2015

Primary Completion Date

April 20, 2017

Study Completion Date

May 15, 2017

Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
DRUG

QVA149

QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily

DRUG

Placebo

Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily

Trial Locations (1)

30625

Novartis Investigative Site, Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY